Newsletter

Commerce Planet: Rumors and Truth

February 27, 2007
Volume VIII, Issue 18
Home Page : www.otcjournal.com
Email Questions or Comments To: editor@otcjournal.com

To OTC Journal Members:
 

Commerce Planet (OTC BB: CPNE): Rumors and Truth

One of the keys to being a successful stock market investor is your ability to learn from the past. There are patterns that repeat themselves, and the quicker you can identify those patterns and learn to profit from them, the more you will enjoy investing in the stock market.

So, now we are faced with a crises of confidence on Commerce Planet, the darling of OTC Journal subscribers. My highly covered #1 pick of 2006 is giving investors are bit of a heart attack in February of 2007.

The stock is behaving as if there is a problem with CPNE. The company is behaving as if it is full steam ahead. The trailing numbers suggest the stock should be considerably higher, and yet it has taken an abrupt drubbing this week.

Long term followers of this company should now take a step back and consider the patterns that could repeat themselves. Consider this chart- This chart goes back to when CPNE released Q3 '06 numbers in October. Look what happened to the stock. Investors pounded it down from $1.80 to a blow off level of just under $1 in a few trading days. Why?- I don't know. The company was immensely profitable, and the stock deserved to go up instead of getting its brains beat out.

Fast forward to mid February of '07. A few days ago the company published "guidance" for the full year, meaning they will report a profit of $.18 EPS for 2006- a full $.07 in Q4.

Once again, the stock gets pounded in an inexplicable manner. Over the past week it has dropped from $3.50 to just under $2.20- another cascade sell off.

So, now let's look at what happened to investors who had the courage to buy CPNE when in got clobbered in early October post Q3 earnings release:

Note: if you had the courage to step in when the stock got clobbered in October at the $1 level, you were rewarded with a 250% gain at the top in a period of four months.

Here's another abrupt sell down just after the market learned of the high profit levels in this company. As Yogi Berra would say, it's Deja Vu all over again. So will the pattern repeat itself?

The market has made us look silly every time we doubted this company. As far as I am concerned, that pattern will continue to repeat itself until proven otherwise. The company has given me no reason to believe their growth is getting derailed. In fact, based on rhetoric coming out of management in their press releases, I believe the company will deliver strong growth in sales and earnings in Q1 of '07- it is also seasonally their strongest period of the year.

There are rumors floating around about 144 filings. For those of you who don't understand what that means, here's the scoop. When a publicly traded company issues shares directly out of treasury to anyone- it could be investors to raise capital, employees, consultants, financiers, etc, those shares are not eligible to be sold into the market. They are described as "Restricted".

There are a number of ways those shares can be eligible to be sold into the public market. Unless newly issued shares are included in a registration statement, they are eligible to become free trading after a period of one year under SEC Rule 144. 

One of the problems that has plagued this particular stock is the dearth of supply coming from early financiers and participants. The company struggled in 2005, and did what it had to do to raise capital. The payment for that capital is probably still coming back to haunt this market in the form of supply.

Here are the facts as they stand today. Since September of 2006, shareholders have filed to sell 2.5 million shares under Rule 144. There could have been very recent 144 filings to sell the stock which haven't hit the SEC yet. New 144 filings could show up any day, and I am now watching. Typically, the shareholder knows he has the legal right to sell before it shows in the SEC filings, so you could be seeing some 144 sellers right now. The filings will show up sooner or later.

In combing through the filings I also learned that JLT Asset Management- a Del Mar California based hedge fund run by Jeffrey Feinberg, has accumulated 3,037,500 shares of CPNE. I don't know him, but I know others that do know him, and I am informed he is very sharp and generates great returns for his investors.

So, there's the facts as they exist today. No rumors. By way of full disclosure I inform subscribers that I have been a seller of CPNE in small amounts for our corporate account when the stock traded well over the last six months. Our position was down to just over 200,000 shares. Today, I have been a buyer of the stock in a couple different accounts. I was trying to buy early under $2.20, but couldn't get any fills. So far, I believe I have purchased about 15,000 shares. I will probably buy more if it stays in this range. I also reserve the right to buy and sell at any time of my choosing following the guidelines set out in the Mission Statement. You can find it on the home page.

Let's hope its Deja Vu all over again. I am betting it is. Keep an eye on the BLOG this week for new information concerning 144 filings. However, once we see them, all they might do is explain the recent down draft in the stock. By then, it should be in the rear view mirror.
 

Subscribe

Information is power and timely information is profitable. Become informed and profit from OTC Journal Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the OTC Journal Email Newsletter on a regular basis.

To ensure newsletter delivery, you can add any additional email addresses you may have to the OTC Journal Member List. Receiving the OTC Journal Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the OTC Journal recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery.

Subscribe Here

Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the OTC Journal, simply follow the instructions located at the bottom of every OTC Journal Newsletter Edition.

Disclaimer
The OTCjournal.com Newsletter is an independent electronic publication committed to providing our readers with factual information on selected  publicly traded companies. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward  maximizing the upside potential for investors while minimizing the downside risk, whenever possible.  Moreover, as detailed below, this publication accepts compensation from certain of the companies which it features.  Likewise, this newsletter is owned by MarketByte, LLC.  To the degrees enumerated herein,  this newsletter should not be regarded as an independent publication.

Go Here to view our compensation on every company we have ever covered, or visit the following web address:  http://www.otcjournal.com/disclaimer.html for our full profiles and http://www.otcjournal.com/trading-alerts/disclaimer.html for Trading Alerts. MarketBtye LLC has been paid of fee of $25,000 in cash and 750,000 newly issued, restricted shares by Commerce Planet  for coverage of the company. All 750,00 have become eligible to be free trading as a result of a registration statement. 

All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

From time to time MarketByte LLC sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.

The editor, members of the editor's family, and/or entities with which they are affiliated aside from MarketBtye LLC itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. Some of the companies featured in the OTC Journal pay a cash ESP fee to an affiliated technology company ranging from $2,000 to $5,000 per month for internet related technology services.

The Trustee of the MarketByte LLC Defined Benefit and Trust (“the MarketByte Pension Plan”) has invested approximately The Trustee of the MarketByte LLC Defined Benefit and Trust (“the MarketByte Pension Plan”) has invested approximately $310,0000 in the Longview Fund (“the Longview Limited Partnership”), a limited partnership in which the MarketByte Pension Plan is a limited partner. No one associated with the MarketByte Pension Plan has any knowledge, information, or control as to any past, present, or future investment activities of the Longview Fund.  Longview ocassoinally refers companies to MarketByte LLC for possible coverage by one of the MarketByte LLC publications, which publications include The OTCJournal.com Newsletter. Longview may or may not own shares in the companies that it so refers to MarketByte. MarketByte has no information (outside of information readily accessible to the general public such as SEC filings) as to whether Longview owns any shares in the companies that it refers to MarketByte LLC.  The above relationships should be viewed as a potential and/or actual conflict of interest by shareholders and prospective shareholders of MarketByte LLC client companies. 

The profiles, critiques, and other editorial content of the OTCjournal.com may contain statements that appear foward relating to the expected capabilities of the companies mentioned herein.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF OTCjournal.com.

We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.govand/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm. Disclaimer ID:$subst('Recip.userid') Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.  MarketByte LLC's mailing address is 4653 Carmel Mtn Rd Suite 308 #402, San Diego, CA 92130.


Unsubscribe Here

You can unsubscribe from this list at any time by Clicking Here and HITTING SEND. If you are having difficulty removing yourself or wish to change your address please go to http://listserv.otcjournal.com/opt.cgi?.

 

Disclaimer

The OTC Journal Newsletter is an electronic publication committed to providing our readers with useful information on publicly traded companies. The Newsletter contracts with publicly traded companies and receives compensation from them or third parties as payment for publishing information and opinions about the company and the trading market for their securities. Principals of the Newsletter may also purchase or sell securities of the companies in the open market from time to time. The positions, if any, that the Newsletter or its principals presently maintain in the securities of the companies are disclosed here (click here) and should be considered in making an investment decision regarding these companies securities. The Newsletter and its principals reserve the right to acquire additional shares or liquidate some or all of the positions they may hold in the issuer’s securities at any time in the future without further notice. These publications should not be considered to be independent publications concerning the company.

All statements and opinions expressed herein are those of the editors and are subject to change without notice. The Newsletter maintains editorial control over its publications and the companies profiled therein do not have any editorial rights concerning the information published about them. While we believe all sources of information provided by us and contained in our publication to be accurate and reliable, we cannot and do not guarantee the accuracy of information we received from third parties.

The information found in this profile is protected by the copyright laws of the United States and may not be copied, or reproduced in any way without the express written consent of the editors of otcjournal.com.

UNSUBSCRIBE

You can unsubscribe from this list at any time by Clicking Here. If you are having difficulty removing yourself or wish to change your address please go to http://www.otcjournal.com/opt/.